Hypereosinophilic syndrome (HES) is a heterogeneous group of disorders characterized by persistent peripheral hypereosinophilia and eosinophilia-mediated tissue damage. Hypereosinophilic syndrome can have life-threatening effects on multiple organ systems but may initially, or in some cases solely, present with skin lesions. The clinical presentation of HES in the skin represents a diagnostic challenge for the dermatologist, because cutaneous manifestations are highly variable and may be mistaken for several dermatologic conditions. Once peripheral and tissue eosinophilia is diagnosed, the differential diagnosis is quite broad, spanning hematoproliferative disorders, infectious diseases, drug reactions, and many others. Workup and management may also present a challenge, because the prospect for organ system involvement in those with apparent skin-limited disease is unclear. This article provides a dermatology-centered approach to HES and provides a reference for the differential diagnosis, workup, and management of this complex disorder.
Get full access to this article
View all access options for this article.
References
1.
ValentP, KlionAD, HornyHP, et al.Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol, 2012; 130(3):607–612.e9.
2.
LeifermanKM, PetersMS. Eosinophil-related disease and the skin. J Allergy Clin Immunol Pract, 2018; 6(5):1462–1482.e6.
3.
ShomaliW, GotlibJ. World Health Organization–defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol, 2019; 94(10):1149–1167.
4.
OgboguPU, RosingDR, HorneMK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am, 2007; 27(3):457–475.
5.
MetzgerothG, WalzC, ErbenP, et al.Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study. Br J Haematol, 2008; 143(5):707–715.
6.
BaccaraniM, CilloniD, RondoniM, et al.The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha–positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 2007; 92(9):1173–1179.
7.
PardananiA, D'SouzaA, KnudsonRA, et al.Long-term follow-up of FIP1L1-PDGFRA–mutated patients with eosinophilia: survival and clinical outcome. Leukemia, 2012; 26(11):2439–2441.
8.
WalzC, ErbenP, RitterM, et al.Response of ETV6-FLT3–positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3. Blood, 2011; 118(8):2239–2242.
9.
SchwaabJ, NaumannN, LuebkeJ, et al.Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol, 2020; 95(7):824–833.
10.
OgboguPU, BochnerBS, ButterfieldJH, et al.Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol, 2009; 124(6):1319–25.e3.
11.
ButterfieldJH. Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha–negative hypereosinophilic syndrome. Leuk Res, 2009; 33(8):1127–1129.
12.
DouC, ChenLYC, DutzJP. Lymphocyte-variant hypereosinophilic syndrome presenting as chronic dermatitis and responding to mycophenolic acid. JAAD Case Rep, 2019; 5(8):660–662.
13.
YadavD, SharmaA, AgarwalS, et al.Hypereosinophilic dermatitis: generalised lichenification and gyrate erythema as the sole manifestation of idiopathic hypereosinophilic syndrome. BMJ Case Rep, 2019; 12(10):e232142.
14.
KemmlerN, PeitschWK, GlorerE, et al.Hypereosinophilic dermatitis. An overlooked diagnosis? [in German]. Hautarzt, 2005; 56(11):1060–1067.
15.
GattringerC, MüllerH, SteurerM, et al.Narrowband UVB therapy for the treatment of pruritus in hypereosinophilic syndrome: clinical report and review of the literature on phototherapy. J Am Acad Dermatol, 2012; 67(5):e210–e213.
16.
RothenbergME, KlionAD, RoufosseFE, et alMepolizumab HES StudyGroup. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med, 2008; 358(12):1215–1228.
17.
RoufosseF, KahnJE, RothenbergME, et alHES Mepolizumab StudyGroup. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol, 2020; 146(6):1397–1405.
18.
KlionAD, LawMA, NoelP, et al.Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood, 2004; 103(8):2939–2941.
19.
ButtgereitT, BonnekohH, ChurchMK, et al.Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. J Dtsch Dermatol Ges, 2019; 17(11):1171–1172.
20.
KuruvillaM. Treatment of hypereosinophilic syndrome and eosinophilic dermatitis with reslizumab. Ann Allergy Asthma Immunol, 2018; 120(6):670–671.
21.
KuangFL, LegrandF, MakiyaM, et al.Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med, 2019; 380(14):1336–1346.
22.
VerstovsekS, TefferiA, KantarjianH, et al.Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia. Clin Cancer Res, 2009; 15(1):368–373.
23.
StratiP, CortesJ, FaderlS, et al.Long-term follow-up of patients with hypereosinophilic syndrome treated with alemtuzumab, an anti-CD52 antibody. Clin Lymphoma Myeloma Leuk, 2013; 13(3):287–291.
24.
KingB, LeeAI, ChoiJ. Treatment of hypereosinophilic syndrome with cutaneous involvement with the JAK inhibitors tofacitinib and ruxolitinib. J Invest Dermatol, 2017; 137(4):951–954.
25.
UenoNT, AnagnostopoulosA, RondónG, et al.Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol, 2002; 119(1):131–134.
26.
BurnsPB, RohrichRJ, ChungKC. The levels of evidence and their role in evidence-based medicine. Plast Reconstr Surg, 2011; 128(1):305–310.
27.
LebwohlMG, HeymannWR, Berth-JonesJ, et al.Treatment of Skin Disease: Comprehensive Therapeutic Strategies. Philadelphia, PA: Elsevier; 2017.
28.
KuangFL, KlionAD. Biologic agents for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol Pract, 2017; 5(6):1502–1509.
29.
PardananiA, BrockmanSR, PaternosterSF, et al.FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood, 2004; 104(10):3038–3045.
30.
ShiM, RechKL, OttesonGE, et al.Prevalence and spectrum of T-cell lymphoproliferative disorders in patients with hypereosinophilia: a reference laboratory experience. Ann Diagn Pathol, 2020; 44:151412.
31.
SimonHU, PlötzSG, DummerR, et al.Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med, 1999; 341(15):1112–1120.
32.
JinJJ, ButterfieldJH, WeilerCR. Hematologic malignancies identified in patients with hypereosinophilia and hypereosinophilic syndromes. J Allergy Clin Immunol Pract, 2015; 3(6):920–925.
33.
HelbigG, Dziaczkowska-SuszekJ, FrancuzT, et al.Frequency of abnormal T-cells in hypereosinophilic syndrome and hypereosinophilia of undetermined significance—extended follow-up. Eur J Intern Med, 2016; 35:e14–e15.
34.
ChenYY, KhouryP, WareJM, et al.Marked and persistent eosinophilia in the absence of clinical manifestations. J Allergy Clin Immunol, 2014; 133(4):1195–1202.
35.
MollerD, TanJ, GauiranDTV, et al.Causes of hypereosinophilia in 100 consecutive patients. Eur J Haematol, 2020; 105(3):292–301.
36.
HuZ, BodduPC, LoghaviS, et al.A multimodality work-up of patients with hypereosinophilia. Am J Hematol, 2018; 93(11):1337–1346.
37.
SadeK, MyselsA, LevoY, et al.Eosinophilia: a study of 100 hospitalized patients. Eur J Intern Med, 2007; 18(3):196–201.
38.
HelbigG, MoskwaA, HusM, et al.Heterogeneity among characteristics of hypereosinophilic syndromes. J Allergy Clin Immunol, 2010; 125(6):1399–401.e2.
39.
InayatF, O'NeillSS, ZafarF, et al.Idiopathic hypereosinophilic syndrome with cutaneous involvement: a comparative review of 32 cases. BMJ Case Rep, 2018; 11(1):bcr2018227137.
40.
PlötzSG, SimonHU, DarsowU, et al.Use of an anti–interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med, 2003; 349(24):2334–2339.
41.
MahajanVK, SinghR, MehtaKS, et al.Idiopathic hypereosinophilic syndrome: a rare cause of erythroderma. J Dermatol Case Rep, 2014; 8(4):108–114.
42.
AbdulsalamMS, GhantaHC, PanduranganP, et al.A case of erythroderma secondary to hypereosinophilia. J Clin Diagn Res, 2016; 10(5):OD15–OD16.
43.
MerlottoMR, CantadoriLO, SakabeD, et al.Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome. An Bras Dermatol, 2018; 93(3):451–453.
44.
UsuiS, DainichiT, KitohA, et al.Janeway lesions and splinter hemorrhages in a patient with eosinophilic endomyocarditis. JAMA Dermatol, 2015; 151(8):907–908.
LeifermanKM, GleichGJ, PetersMS. Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am, 2007; 27(3):415–441.
47.
OhtaniT, OkamotoK, KaminakaC, et al.Digital gangrene associated with idiopathic hypereosinophilia: treatment with allogeneic cultured dermal substitute (CDS). Eur J Dermatol, 2004; 14(3):168–171.
48.
JangKA, LimYS, ChoiJH, et al.Hypereosinophilic syndrome presenting as cutaneous necrotizing eosinophilic vasculitis and Raynaud's phenomenon complicated by digital gangrene. Br J Dermatol, 2000; 143(3):641–644.
49.
YuZ, DeeEC, MengeT, et al.Skin-limited idiopathic hypereosinophilic syndrome presenting with retiform purpura. JAAD Case Rep, 2019; 5(8):742–745.
50.
KimT, KimMR, KimJH, et al.Extensive digital gangrene without evidence of large-vessel occlusion in hypereosinophilic syndrome. Acta Derm Venereol, 2011; 91(3):365–366.
51.
OppligerR, Gay-CrosierF, DayerE, et al.Digital necrosis in a patient with hypereosinophilic syndrome in the absence of cutaneous eosinophilic vasculitis. Br J Dermatol, 2001; 144(5):1087–1090.
52.
HamadaT, KimuraY, HayashiS, et al.Hypereosinophilic syndrome with peripheral circulatory insufficiency and cutaneous microthrombi. Arch Dermatol, 2007; 143(6):812–813.
53.
GambichlerT, KrögerES, TannapfelA, et al.Hypereosinophilic syndrome complicated by severe vascular damage and gangrene. J Vasc Surg Cases Innov Tech, 2019; 5(3):384–387.
54.
LefèvreG, LeursA, GibierJB, et alCEREO—French National Reference Center for HypereosinophilicSyndromes. “Idiopathic eosinophilic vasculitis”: another side of hypereosinophilic syndrome? A comprehensive analysis of 117 cases in asthma-free patients. J Allergy Clin Immunol Pract, 2020; 8(4):1329–40.e3.
55.
SuzukiH, FukuiR, TabataN, et al.Rare manifestation of hypereosinophilic syndrome: diffuse-type hair loss with massive perifollicular eosinophils. J Dermatol, 2020; 47(1):61–63.
56.
OffidaniA, BernardiniML, SimonettiO, et al.Hypereosinophilic dermatosis: skin lesions as the only manifestation of the idiopathic hypereosinophilic syndrome?. Br J Dermatol, 2000; 143(3):675–677.
57.
LiD, XuL, LinD, et al.Acute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome. Respir Med Case Rep, 2018; 25:213–215.
58.
AkuthotaP, WellerPF. Spectrum of eosinophilic end-organ manifestations. Immunol Allergy Clin North Am, 2015; 35(3):403–411.
59.
SheikhJ, WellerPF. Clinical overview of hypereosinophilic syndromes. Immunol Allergy Clin North Am, 2007; 27(3):333–355.
60.
ChuaCE, LingV, JingM, et al.An unusual presentation of idiopathic hypereosinophilic syndrome. J Thromb Thrombolysis, 2020; 50(2):473–476.
61.
PlötzSG, HüttigB, AignerB, et al.Clinical overview of cutaneous features in hypereosinophilic syndrome. Curr Allergy Asthma Rep, 2012; 12(2):85–98.
62.
SchusterB, ZinkA, EyerichK. Medical algorithm: diagnosis and treatment of hypereosinophilic syndrome. Allergy, 2020; 75(11):3003–3006.
63.
LongH, ZhangG, WangL, et al.Eosinophilic skin diseases: a comprehensive review. Clin Rev Allergy Immunol, 2016; 50(2):189–213.
64.
TsujiY, KawashimaT, YokotaK, et al.Wells' syndrome as a manifestation of hypereosinophilic syndrome. Br J Dermatol, 2002; 147(4):811–812.
65.
AmberKT, ValdebranM, KridinK, et al.The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease. Front Med (Lausanne), 2018; 5:201.
66.
KridinK. Peripheral eosinophilia in bullous pemphigoid: prevalence and influence on the clinical manifestation. Br J Dermatol, 2018; 179(5):1141–1147.
67.
KobayashiS, InokumaS, SetoguchiK, et al.Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases. Allergy, 2002; 57(10):950–956.
68.
SimonD, BraathenLR, SimonHU. Eosinophils and atopic dermatitis. Allergy, 2004; 59(6):561–570.
69.
LyMN, BethelSL, UsmaniAS, et al.Cutaneous strongyloides stercoralis infection: an unusual presentation. J Am Acad Dermatol, 2003; 49(2suppl case reports):S157–S160.
70.
QuimbySR, ConnollySM, WinkelmannRK, et al.Clinicopathologic spectrum of specific cutaneous lesions of disseminated coccidioidomycosis. J Am Acad Dermatol, 1992; 26(1):79–85.
71.
ButtNM, LambertJ, AliS, et alBritish Committee for Standards inHaematology. Guideline for the investigation and management of eosinophilia. Br J Haematol, 2017; 176(4):553–572.
72.
SluzevichJC, ShethAP, LuckyAW. Persistent eosinophilia as a presenting sign of scabies in patients with disorders of keratinization. Arch Dermatol, 2007; 143(5):670–673.
73.
RobertsLJ, HuffamSE, WaltonSF, et al.Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect, 2005; 50(5):375–381.
74.
RoujeauJC, HaddadC, PaulmannM, et al.Management of nonimmediate hypersensitivity reactions to drugs. Immunol Allergy Clin North Am, 2014; 34(3):473–487.
75.
CacoubP, MusetteP, DescampsV, et al.The DRESS syndrome: a literature review. Am J Med, 2011; 124(7):588–597.
76.
ChoudharyS, McLeodM, TorchiaD, et al.Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol, 2013; 6(6):31–37.
77.
HusainZ, ReddyBY, SchwartzRA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol, 2013; 68(5):693.e1–693.e14.
78.
ShioharaT, MizukawaY. Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): an update in 2019. Allergol Int, 2019; 68(3):301–308.
79.
DevarbhaviH, RajS. Drug-induced liver injury with skin reactions: drugs and host risk factors, clinical phenotypes and prognosis. Liver Int, 2019; 39(5):802–811.
80.
KhouryP, MakiyaM, KlionAD. Clinical and biological markers in hypereosinophilic syndromes. Front Med (Lausanne), 2017; 4:240.
81.
BaerC, MuehlbacherV, KernW, et al.Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. Haematologica, 2018; 103(8):e348–e350.
82.
LefèvreG, CopinMC, Staumont-SalléD, et alFrench EosinophilNetwork. The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype. Medicine (Baltimore), 2014; 93(17):255–266.
83.
HuZ, WangW, ThakralB, et al.Lymphocytic variant of hypereosinophilic syndrome: a report of seven cases from a single institution. Cytometry B Clin Cytom, 2021; 100(3):352–360.
84.
RoufosseF, GaraudS, de LevalL. Lymphoproliferative disorders associated with hypereosinophilia. Semin Hematol, 2012; 49(2):138–148.
85.
MaricI, RobynJ, MetcalfeDD, et al.KIT D816V–associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. J Allergy Clin Immunol, 2007; 120(3):680–687.
86.
SimonHU, RothenbergME, BochnerBS, et al.Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol, 2010; 126(1):45–49.
87.
JovanovicJV, ScoreJ, WaghornK, et al.Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA–positive chronic eosinophilic leukemia. Blood, 2007; 109(11):4635–4640.
Forero MolinaMA, CoffeyKE, ChongHJ. Successful treatment of idiopathic hypereosinophilic syndrome with benralizumab in a pediatric patient. J Allergy Clin Immunol Pract, 2021; 9(1):589–590.
90.
FujiiK, TakahashiH, HayakawaN, et al.Idiopathic hypereosinophilic syndrome in remission with benralizumab treatment after relapse with mepolizumab. Respirol Case Rep, 2020; 8(8):e00665.
91.
Alen CoutinhoI, RegateiroFS, LoureiroC, et al.Benralizumab in severe and refractory PDGFRA-negative hypereosinophilic syndrome. J Clin Immunol, 2021; 41(3):688–690.
92.
WieserJK, KuehnGJ, PrezzanoJC, et al.Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment. JAAD Case Rep, 2020; 6(4):292–295.
93.
d'ElbéeJM, ParrensM, MerciéP, et al.Hypereosinophilic syndrome—lymphocytic variant transforming into peripheral T-cell lymphoma with severe oral manifestations. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013; 116(3):e185–e190.
94.
PodjasekJC, ButterfieldJH. Mortality in hypereosinophilic syndrome: 19 years of experience at Mayo Clinic with a review of the literature. Leuk Res, 2013; 37(4):392–395.
